{"meta":{"query_hash":"648732e8aed1","filters":{"venue":"Biosimilars"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/648732e8aed1","api":"https://metacan.xera.ac/api/v1/cohort?venue=Biosimilars"},"results":[{"id":"W2124630617","doi":"10.2147/bs.s20577","title":"Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics","year":2011,"lang":"en","type":"article","venue":"Biosimilars","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Amgen","keywords":"Interchangeability; Drug; Medicine; Pharmacology; Business; Biosimilar; Risk analysis (engineering); Intensive care medicine; Computer science; Internal medicine","score_opus":0.15432901733991708,"score_gpt":0.32945311233849545,"score_spread":0.17512409499857837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124630617","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27240416,0.098088786,0.5076075,0.025543464,0.002347848,0.0062472876,0.0020612737,0.0006189358,0.08508079],"genre_scores_gemma":[0.81379795,0.010189911,0.16672565,0.0028802264,0.0017488358,0.0017813883,0.000950704,0.000084445186,0.0018407878],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.737966,0.14140539,0.029760014,0.0043030204,0.08571777,0.0008477846],"domain_scores_gemma":[0.54637396,0.35296503,0.05346571,0.009686145,0.036401793,0.0011074533],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2081824,0.00069489295,0.0011780183,0.0069910428,0.0010172151,0.003761504,0.0016681515,0.0023644723,0.0037549695],"category_scores_gemma":[0.27101687,0.00038918626,0.0021411863,0.0052709305,0.0036285317,0.0035954693,0.0019383,0.0028680149,0.00073939224],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033306468,0.0007649471,0.12476738,0.0063212737,0.001077236,0.0003212071,0.0011176247,0.0059702136,0.011165817,0.046041247,0.008770547,0.7903519],"study_design_scores_gemma":[0.0012348248,0.018289015,0.45829195,0.010335536,0.005088181,0.0077780737,0.002492607,0.067486085,0.100327,0.13273787,0.19528066,0.0006582274],"about_ca_topic_score_codex":0.00065323536,"about_ca_topic_score_gemma":0.00052624627,"teacher_disagreement_score":0.2081824,"about_ca_system_score_codex":0.0034668404,"about_ca_system_score_gemma":0.0038449375,"threshold_uncertainty_score":0.97645205},"labels":[],"label_agreement":null}]}